While safety and tolerability have traditionally been used as go/no-go criteria in early-phase clinical trials (Stallard et al., 2001), a growing repertoire of biomarkers that can be used to evaluate short-term intervention effects, such as target engagement, pharmacodynamics, and effects predictive of clinical benefit, may additionally be used to inform go/no-go decisions and over time begin to reduce the number of negative phase 3 clinical trials (Boxer and Sperling, 2023
If fatigue persists beyond two weeks, assess your total caloric intake
(2021) Vitamin B12 supplementation in diabetic neuropathy: a 1-year, randomized, double-blind, placebo-controlled trial
You are comparing research-peptide vendors and Prime Peptides keeps showing up, with a testing page, a verify portal, and fast shipping
For someone who hasn't responded adequately to supplements, DSIP represents a more potent intervention
Principal investigators of the included studies were contacted for additional information as needed
